We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+13.5%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.9B
AUM Growth
+$430M
Cap. Flow
-$2.03B
Cap. Flow %
-9.27%
Top 10 Hldgs %
51.69%
Holding
190
New
27
Increased
30
Reduced
39
Closed
32

Top Buys

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$731M
2
HES
Hess
HES
+$436M
3
NDAQ icon
Nasdaq
NDAQ
+$341M
4
SPLK
Splunk Inc
SPLK
+$157M
5
UTHR icon
United Therapeutics
UTHR
+$110M

Top Sells

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$1.9B
2
VMW
VMware, Inc
VMW
+$915M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$770M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$482M
5
AON icon
Aon
AON
+$216M

Sector Composition

Rank Sector Weight
1 Healthcare 27.49%
2 Technology 11.1%
3 Financials 9.67%
4 Industrials 6.16%
5 Communication Services 5.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCRMW
126
DELISTED
Screaming Eagle Acquisition Corp. Warrant
SCRMW
$150K ﹤0.01%
333,330
– –
COGT icon
127
Cogent Biosciences
COGT
$6.37B
$100K ﹤0.01%
17,000
– –
SLDPW icon
128
Solid Power Inc Warrant
SLDPW
$6.93M
$78.1K ﹤0.01%
405,316
– –
SEPAW
129
DELISTED
SEP Acquisition Corp Warrants
SEPAW
$65K ﹤0.01%
866,250
– –
KCGI.WS
130
DELISTED
Kensington Capital Acquisition Corp. V Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
KCGI.WS
$58.1K ﹤0.01%
581,400
– –
VSTEW
131
DELISTED
Vast Renewables Limited Warrants
VSTEW
$56.3K ﹤0.01%
+450,000
New +$54.6K
GATEW
132
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$44.5K ﹤0.01%
1,485,000
– –
IVCPW
133
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
$42.6K ﹤0.01%
990,000
– –
RVMDW icon
134
Revolution Medicines Inc Warrant
RVMDW
$130M
$39.6K ﹤0.01%
+120,085
New +$53.6K
CVIIW
135
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$35.8K ﹤0.01%
200,000
– –
SEDA.WS
136
DELISTED
SDCL EDGE Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary share at an exercise price of $11.50
SEDA.WS
$27.3K ﹤0.01%
866,250
– –
RCFA.WS
137
DELISTED
RCF Acquisition Corp. Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
RCFA.WS
$23.3K ﹤0.01%
300,000
– –
GHIXW
138
DELISTED
Gores Holdings IX, Inc. Warrant
GHIXW
$20K ﹤0.01%
166,664
– –
NVNIW
139
Nvni Group Limited Warrants
NVNIW
$13.3K ﹤0.01%
+375,000
New +$20.8K
BCSAW
140
DELISTED
Blockchain Coinvestors Acquisition Corp. I Warrant
BCSAW
$9.22K ﹤0.01%
150,000
– –
CITEW
141
DELISTED
Cartica Acquisition Corp Warrant
CITEW
$8.22K ﹤0.01%
175,000
– –
LCAHW
142
DELISTED
Landcadia Holdings IV, Inc. Warrant
LCAHW
$8.11K ﹤0.01%
125,000
– –
JWSM.WS
143
DELISTED
Jaws Mustang Acquisition Corp. Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
JWSM.WS
$7.94K ﹤0.01%
200,000
– –
SLACW
144
DELISTED
Social Leverage Acquisition Corp I Redeemable warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
SLACW
$6.32K ﹤0.01%
187,500
– –
LGVCW
145
DELISTED
LAMF Global Ventures Corp. I Warrant
LGVCW
$4.6K ﹤0.01%
200,000
– –
AEON.WS
146
DELISTED
AEON Biopharma Inc
AEON.WS
$4.37K ﹤0.01%
49,995
– –
SLAMW
147
DELISTED
Slam Corp. warrant
SLAMW
$3.35K ﹤0.01%
17,627
– –
RGTIW icon
148
Rigetti Computing Warrants
RGTIW
$178M
$2.95K ﹤0.01%
22,675
– –
MVLAW
149
DELISTED
Movella Holdings Inc. Warrant
MVLAW
$2.7K ﹤0.01%
150,000
– –
AKRO
150
DELISTED
Akero Therapeutics
AKRO
– –
-4,000
Closed -$202K
4 5
6
7 8

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2023 Portfolio in Review

As of Q4 2023, Thomas Steyer held 190 positions worth $21.9B, up 2% from $21.4B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Thomas Steyer withdrew a net $2.03B in Q4 2023, closing 32 positions and reducing 39 holdings. Its most notable exit was Activision Blizzard, an estimated $1.9B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 31% a quarter earlier, followed by Technology and Financials.

Against the trend, Thomas Steyer opened a new position in Pioneer Natural Resource Co. worth $702M.

  • Thomas Steyer's largest Q4 2023 buy was Pioneer Natural Resource Co.: 3,120,000 shares worth $702M.
  • Thomas Steyer added most to Nasdaq in Q4 2023, an estimated $341M increase.
  • Thomas Steyer's biggest Q4 2023 reduction was AstraZeneca, cutting an estimated $145M.
  • Thomas Steyer fully exited Activision Blizzard in Q4 2023, selling an estimated $1.9B.
  • Thomas Steyer's ten largest holdings make up 52% of its $21.9B portfolio in Q4 2023.
  • Thomas Steyer opened 27 new positions and closed 32 in Q4 2023.
  • Thomas Steyer's portfolio value rose 2% quarter-over-quarter to $21.9B.

Based on Farallon Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.